EosGene Tx
Our strategy
1. Scale up manufacturing and de-risk the technology by collecting relevant scientific evidence 2. Demonstrate therapeutic effect in an animal disease model of a monogenic genetic disease diabetic retinopathy - our initial target. 3. Build an IP portfolio around our technology 4. Partner with major Pharma/Biotech and establish contract manufacturing for the targeted disease. 5. Form clinical and commercial partnerships to facilitate clinical trials on gene therapeutics using our technology 6. Develop the necessary regulatory documentation for submission and launch commercialisation
We plan to develop commercial lipid nanoparticles
for the delivery off genetic therapies including CRISPR
OUR BUSINESS MODEL
Conduct extensive preclinical studies using relevant disease models and cell lines to evaluate the effectiveness of liposome-formulated CRISPR editing. Perform comprehensive safety assessments to identify potential adverse effects associated with CRISPR editing, including the immunogenicity, cytotoxicity, and potential off-target effects of the CRISPR components and liposomes. Compare the efficacy, safety, and scalability of liposome approaches with alternative delivery systems to demonstrate its advantages and value.
Develop and optimize a robust and reproducible manufacturing process for producing liposomes, with considering batch-to-batch consistency, scalability, and cost-effectiveness during process development. Implement robust quality control measures to ensure the consistency and safety of the manufactured liposomes. Develop analytical methods to assess critical quality attributes (CQAs), such as size distribution, encapsulation efficiency, stability, and purity. Align the developments with regulatory guidelines specific to gene therapy and liposome -based products.
Engage IP professionals with expertise in the biotechnology and nanoparticle field. As appropriate, file continuation or divisional applications to further protect different aspects or embodiments of our liposome technology
Manufacturing partners
RNA Institute
​
​
​
R&D partners
University of New South Wales
University of Technology, Sydney
Clinical
partners
Westmead Hospital, Sydney
Royal North Shore Hospital
Other partners
NSW Health
UNSW Knowledge Exchange
UNSW Founders
​
Commercial
partners
Sought